🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06358807
Recruiting Not applicable

Microfracture With Platelet Rich Plasma Gel Injection for Osteochondral Lesion of the Talus

NCT06358807 · tracked via the Priya Life Science China tracker
Sponsor
Peking University Third Hospital
Phase
Not applicable
Started
2024-01-01
Last updated
2024-05-20

Condition(s) studied

Osteochondral Lesion of TalusMicrofracturesPlatelet Rich Plasma

Investigational drug(s) / intervention(s)

Arthroscopic microfracture with intraoperative local PRP gel injectionIsolated microfracture

Arthroscopic microfracture with intraoperative local PRP gel injection: Arthroscopic microfracture: An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion. PRP preparation and local injection: PRP is harvested using a PRP preparation kit via centrifugation. Fifty milliliters of autologous venous blood are drawn from the patient and processed. Platelet count is measured for quality control. On average 4 ml of (range 3-6) PRP is obtained and mixed with thrombin calcium agent in preparation for PRP gel. PRP gel is administered to the injured area using a blunt and long-tip injector, with direct visualization under arthroscope.

Isolated microfracture: Arthroscopic microfracture: An anteromedial portal and an anterolateral portal are routinely established. A diagnostic arthroscopy is performed. Defects of superficial cartilage, cystic components, and necrotic bone are debrided arthroscopically with curette and shaver to a stable circumferential rim. Microfracture awls are introduced and subchondral channels to 4-6 mm in depth are created, spacing the channels 3 to 5 mm apart across the entire surface of the lesion.

Study summary

The goal of this clinical trial is to learn if combined local injection of platelet rich plasma (PRP) gel adds clinical efficacy to isolated arthroscopic microfracture in treatment of osteochondral lesion of the talus (OLT). The interface integration of the injured area will also be assessed via radiographic follow-up. The main questions it aims to answer are:

* Does arthroscopic microfracture combined with PRP gel injection improve ankle function of participants based on American Orthopedic Foot and Ankle Society (AOFAS) Score?
* Does arthroscopic microfracture combined with PRP gel injection improve interface integration of the injured cartilage on magnetic resonance imaging (MRI)? Researchers will compare arthroscopic microfracture with concomitant local injection of PRP gel to isolated microfracture to see if intraoperative PRP gel injection adds clinical efficacy to isolated arthroscopic microfracture in treatment of OLT.

Participants will:

* Undergo either isolated arthroscopic microfracture or microfracture with intraoperative injection of PRP gel
* Receive clinical follow-up 3, 6, 12, and 24 months after surgery and answer scales of ankle function assessment
* Take MRI preoperatively and 6, 12 and 24 months after surgery

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Chronic ankle pain, diagnosed as osteochondral lesion of the talus; * Lesion size ≤ 1.5 cm2 or the diameter of the lesion ≤ 1.5 cm; * Conservative treatment of at least 3 months fails to relieve symptoms; * Willingness to voluntarily participate in the trial and to sign informed consent. Exclusion Criteria: * Varus or valgus deformity of the ankle of more than 5 degrees; * Grade III injury of the lateral collateral ligament of ankle; * Chronic synovitis (rheumatoid arthritis, pigmented villous nodular synovitis, etc.); * Joint fibrosis, stiffness, and significantly restricted range of motion; * Evidence of moderate to severe knee osteoarthritis on plain radiographs; * Failure to complete the rehabilitation protocol as required; * Patient medically not fit for surgery, radiographs or MRI; * For women, pregnant, planning to be pregnant or lactating.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University Third Hospital Beijing China Recruiting

More Peking University Third Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06358807 on ClinicalTrials.gov ↗ ← All trials in China